Predicta Biosciences’ Post

SFBN Feed: Unpacking IRA price negotiations results; Lykos’ tough week; Genentech rethinks cancer immunology; and more https://lnkd.in/gcm3Entw Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

🔬 Breaking: $181M Funding Round Signals Major ADC Market Momentum Novo Holdings, OrbiMed, and Jeito have just led a significant $181M investment in Antibody-Drug Conjugates (ADCs), marking one of this quarter's largest biotech funding rounds. TL;DR: • Major funding secured for ADC development • Led by top-tier life science investors • Signals growing market confidence in targeted cancer therapeutics This investment validates the increasing importance of ADCs in oncology therapeutics and reflects the industry's shift toward more precise, personalized treatment approaches. Strategic Takeaways: 1. Time to evaluate your R&D portfolio's ADC potential 2. Consider strategic partnerships in the ADC space 3. Watch for emerging regulatory frameworks 4. Monitor competitive landscape developments 💡 What's your take on ADCs' future in oncology? Are you seeing similar investment patterns in your sector? Share your insights below. #Biotech #CancerTherapeutics #ADC #BiotechInvestment #Oncology #pharma #biotech #medicinetomarket

Will you attend Swiss Biotech Day 2024 In Basel? Join our panel of "ADCs and Beyond" on Monday, April 22th. With the approval of trastuzumab deruxtecan (Enhertu) in 2019, we have been witnessing the soaring numbers of both preclinical and clinical ADC assets as well as a number of eye-catching investments and licensing deals in this field. What could be the development strategies for the next generation of ADCs? What are the potentials on other bioconjugates other than typical ADCs (i.e. XDC)? Can the therapeutic areas be expanded beyond oncology? Join our panel of varied industry experts and explore these topics. Find out more about the event: https://lnkd.in/dfseDhjc #swissbiotechday #swissbiotechday2024 #ADC #Bioconjugate #ADCdisocvery #ADCdevelopment #ADCmanufacturing #CDMO

Stay up to date on all things #IO and register for tomorrow's #SITC Targets for Cancer IO: A Deep Dive into Clinical Consideration for CD3-Bispecifics and Costimulatory T cell Engagers in Solid #Tumors Webinar! Moderators: Jeremy Myers, PhD - EvolveImmune Therapeutics & Dimitris Skokos, PhD - Regeneron Pharmaceuticals, Inc. Faculty: John Desarjais, PhD - Xencor, Christian Klein, PhD - Roche Innovation Center Zurich & Elizabeth Pham, PhD - Amgen Inc. This webinar will address current studies to develop more effective, safer CD3-targeting bispecific T #cell engagers that maintain clinical efficacy within the immunosuppressive #TME while minimizing cytokine release and other on-target, off-tumor toxicities. Save your spot for tomorrow's webinar: go.sitcancer.org/3YtTUNh

🔬 Biotech News: Pyxis Oncology ADC Trial Results Impact Market TL;DR: 📉 Pyxis Oncology experiences significant stock decline following underwhelming initial results from their solid tumor ADC trials. 🔍 Key Implications: • Market reaction underscores volatility in ADC investments • Highlights critical importance of robust clinical data • May influence broader ADC technology sentiment 💡 Strategic Takeaways for Biotech Leaders: • Monitor ADC landscape developments closely • Implement rigorous trial design protocols • Maintain transparent milestone communication • Consider R&D portfolio diversification What are your thoughts on the future of ADC technologies in oncology? Share your insights below. #BiotechNews #Oncology #DrugDevelopment #ClinicalTrials #ADC #pharma #biotech #medicinetomarket

Pillar Biosciences Incorporated and AstraZeneca have announced a partnership to advance NGS-based liquid biopsy testing in Europe! 🌍🔬 This new partnership aims to leverage Pillar Biosciences Incorporated OncoReveal LBx panel to rapidly identify tumors with clinically actionable genomic alterations via liquid biopsy profiling while supporting faster diagnostic testing. "Access to cost effective, easy to use, distributed NGS kits for liquid biopsy testing are critical to support local laboratories in providing clinically actionable results to oncologists and supporting critical treatment decisions for cancer patients globally," - Dan Harma 👏 Great to see another partnership like my post last week on Illumina, Bayer & Eli Lilly and Company! 👏👏👏 #CancerResearch #LiquidBiopsy #HealthcareInnovation #Partnership #PersonalizedMedicine #NGS

📣We are delighted to announce a strategic collaboration with CTI Clinical Trial and Consulting Services, a renowned full-spectrum research services provider, to bolster oncology-focused consulting services. This partnership combines decades of expertise from both organizations in oncology drug discovery and development, leveraging Crown Bioscience’s preclinical and translational models and CTI’s well-established track record in the clinical and regulatory space. Customers will benefit from the combined expert guidance, supporting the transition of oncology compounds from discovery through early-phase global trials more rapidly and effectively. This alliance aims to determine the best and most expeditious path to the clinic, ensure long-term drug development success and growth, and accelerate the delivery of more oncology therapeutics to patients. Read the full release here ➡️https://hubs.la/Q02M2QsT0 #Biotech #Bioscience #Oncology #DrugDevelopment

Araris Biotech AG, with its proprietary conjugation technology and linker-payload platforms to efficiently develop and advance next-generation ADCs, is one of the seven innovative companies listed in the Clarivate Companies to Watch report this year. Araris' drug attachment is simple, site-specific and has the potential to stably accommodate various drug-load combinations without altering the pharmacokinetic profile of the antibody, resulting in ADCs with a high therapeutic window. Why is Araris Biotech a company to watch?      Download the report to discover innovations transforming drug discovery and development, revolutionizing cancer treatment, and capturing big pharma interest, here: https://lnkd.in/eCSaAWtu #oncology #cancertreatement #biotech #pharma #companiestowatch

🎯 Join the Innovation in Oncology with BiPER Therapeutics! We are developing a revolutionary drug candidate for gastrointestinal cancers. Our unique approach focuses on the metabolism of cancer cells, addressing unmet medical needs. 🛠️ Support our crowdfunding campaign and be part of the future of oncology: BiPER Therapeutics is seeking to raise €500,000 through convertible bonds to finance essential regulatory toxicology studies. 🔑 Why invest in BiPER Therapeutics? • Recognized innovation: Winner of the Matwin OUI Investor Prize 2021, i-Lab 2022, and Challenges 2023. • Growing market: A global market potential of $2.5 billion per year. • Scientific strength: 7 patents filed, in collaboration with Inserm and CNRS. • Unique position: No direct competitors for gastrointestinal cancers. • International interest: Significant interest from pharmaceutical laboratories and institutional funds. 👉 Join us and invest in the medicine of tomorrow! https://lnkd.in/eGvZHznQ With your support, we can transform oncology care. Thank you for your trust and contribution! #Oncology #Innovation #Biotechnology #Investment #Health #Startup

Our work, titled "Machine Learning-Based Prediction of Lung Cancer Using Biomarker Data," ably presented by Uma J. was awarded Best Oral Presentation at the International Conference on Biotechnology and Biomedical Research held on September 19-20, 2024, in Goa, India, organized by the Association of Pharmaceutical Research (APR). This work focuses on leveraging AI to enhance early detection of lung cancer through non-invasive biomarker analysis. Manasi Kulkarni-Khasnis Snahlata Singh Atharva Joshi Jahnavi Kulkarni Jaithya Suseel A heartfelt thanks to the organizers, fellow researchers, and attendees for the enriching discussions and feedback. This recognition inspires us to continue innovating at the intersection of AI and healthcare to drive impactful outcomes. #MachineLearning #LungCancer #Biotechnology #BiomedicalResearch #AIinHealthcare #CancerResearch #APR2024